Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942760 · ClinicalTrials.gov registry record
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas
A clinical trial of Recurrent High Grade Gliomas, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT00942760 is a study of Recurrent High Grade Gliomas that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00942760, a study of Recurrent High Grade Gliomas, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a tissue sample. The hypotheses of the study is to determine if multimodal MR technique will provide tissue signatures that differentiate between tumor progression and treatment related necrosis in high grade glioma patients.
Conditions Studied
Interventions
- DEVICE 3T MRI
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942760
The ClinicalTrials.gov registry entry for NCT00942760 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent High Grade Gliomas appearing as the primary indexed condition, and to 1 intervention - of which 3T MRI is the first listed.
NCT00942760 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00942760 about?
NCT00942760 is a clinical study titled "Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas". Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a tissue sample. The hypotheses of the study is to determine if multimodal...
What is the current status of trial NCT00942760?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2009-04. Estimated completion is 2011-04.
What conditions does trial NCT00942760 study?
This clinical trial studies the following conditions: Recurrent High Grade Gliomas.
What interventions are being tested in trial NCT00942760?
The interventions under investigation include: 3T MRI (DEVICE).
Who is sponsoring clinical trial NCT00942760?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00942760 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.